English
Specials
    Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsRanbaxylaboratories

    Stock analysis is used by traders to make buy and sell call. It’s an approach to make informed decisions while investing in stocks. Stock analysis can be categorised into – fundamental analysis and technical analysis. Fundamental analysis is evaluation of data from sources, including financial records, economic reports, company assets, and market share. Analysts typically study the company’s financial statements – balance sheet, income statement, cash flow statement, and footnotes. These statements are made available to the investors in the form of quarterly earnings, disclosures to stock exchanges in compliance with the Securities and Exchange Board of India (Sebi) norms. In fundamental analysis, the analysts particularly check for a company's core income, income from other sources, profitability, guidance, assets and liabilities and debt ratio among other parameters. The other method, i.e. the technical analysis focuses purely on statistical data. It works on two assumptions; one, the stock price reflects the fundamentals. Second, the study of past and present movement in prices can help determine the future price trends. Technical analysis primarily deals with price, volume, demand and supply factors. This method is effective only when supply and demand forces influence the market. However, when outside factors are involved in a price movement, technical analysis may not be successful. More

    Jump to
    • Ranbaxy looks better in pharma space: Bothra

      Ranbaxy looks better in pharma space: Bothra

      Ranbaxy is looking better pick in pharma space, says Kunal Bothra of LKP.

    • Ranbaxy has target of Rs 520-530: Prashastha Seth

      Ranbaxy has target of Rs 520-530: Prashastha Seth

      Ranbaxy Laboratories has target of Rs 520-530, says Prashastha Seth, Senior VP IIFL Private Wealth, IIFL.

    • Ranbaxy can touch Rs 520: Rakesh Gandhi

      Ranbaxy can touch Rs 520: Rakesh Gandhi

      Ranbaxy can touch Rs 520, says Rakesh Gandhi, LKP.

    • Ranbaxy may shoot 10% in short-term: Jai Bala

      Ranbaxy may shoot 10% in short-term: Jai Bala

      Ranbaxy Laboratories can add 10% in the short term , says Jai Bala, Chief Market Technician, Cashthechaos.com.

    • Buy Ranbaxy on 14-15% correction: Baliga

      Buy Ranbaxy on 14-15% correction: Baliga

      Buy Ranbaxy on 14-15% correction, says Ambareesh Baliga, COO, Way2Wealth.

    • Ranbaxy has target of Rs 451: Thununguntla

      Ranbaxy has target of Rs 451: Thununguntla

      Ranbaxy Laboratories has target of Rs 451, says Jagannadham Thununguntla, Head of Research, SMC Global.

    • Stay invested in Ranbaxy Labs: Phani Sekhar

      Stay invested in Ranbaxy Labs: Phani Sekhar

      Phani Sekhar, Fund Manager, Angel Broking is of the view that stay invested in Ranbaxy Laboratories with longer-term perspective.

    • Ranbaxy Labs can add another Rs 100: Sushil Kedia

      Ranbaxy Labs can add another Rs 100: Sushil Kedia

      Sushil Kedia, FRM, CAIA, CMT, President - Association of Technical Market Analysts (ATMA) feels that Ranbaxy Laboratories can add another Rs 100 from current level.

    • Ranbaxy Labs may slip to Rs 400: Thacker

      Ranbaxy Labs may slip to Rs 400: Thacker

      Ranbaxy Labs may slip to Rs 400, says Mitesh Thacker, Technical Analyst, miteshthacker.com.

    • Avoid taking positions in Ranbaxy Labs: Gandhi

      Avoid taking positions in Ranbaxy Labs: Gandhi

      Avoid taking positions in Ranbaxy Labs, says Rakesh Gandhi, Sr Technical Analyst, LKP.

    • Ranbaxy looks expensive: IIFL Capital

      Ranbaxy looks expensive: IIFL Capital

      Ranbaxy Laboratories is looking expensive at these levels, says Bino Pathiparampil, Vice President of IIFL Capital.

    • See some more pain in Ranbaxy: Thukral

      See some more pain in Ranbaxy: Thukral

      See some more pain in Ranbaxy Laboratories, says Hemant Thukral, SBI Securities.

    • Ignore Ranbaxy Laboratories: Baliga

      Ignore Ranbaxy Laboratories: Baliga

      Ignore Ranbaxy Laboratories, says Ambareesh Baliga, Karvy Stock Broking.

    • Ranbaxy can slip to Rs 440-445: Kulkarni

      Ranbaxy can slip to Rs 440-445: Kulkarni

      Ranbaxy Laboratories can slip to Rs 440-445, says Shardul Kulkarni, Angel Broking.

    • Accumulate Ranbaxy, says Phani Sekhar

      Accumulate Ranbaxy, says Phani Sekhar

      Accumulate Ranbaxy Laboratories, says Phani Sekhar, Fund Manager, Angel Broking.

    • Ranbaxy Lab can add 30-35%: Dilip Bhat

      Ranbaxy Lab can add 30-35%: Dilip Bhat

      Ranbaxy Laboratories can add 30-35%, says Dilip Bhat, Joint MD, Prabhudas Lilladher.

    • Pick Ranbaxy, Cipla for long term: Bothra

      Pick Ranbaxy, Cipla for long term: Bothra

      Pick Ranbaxy and Cipla for long term, says Kunal Bothra of LKP.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347